Keros Therapeutics, Inc. (KROS) is a Lexington, Massachusetts–based clinical-stage biopharmaceutical company developing therapies that target dysfunctional signaling of the transforming growth factor-beta family of proteins. Its lead wholly owned asset, rinvatercept, is in Phase 2 testing for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while elritercept is partnered with Takeda for myelodysplastic syndromes and myelofibrosis. Shares of KROS were trading at $12.04, up 6.45%, against the prior session's close of $11.31. The move extends Tuesday's 12.76% advance and confirms a bullish two-day reversal. The immediate driver cited by the market is the company's new $5 million buyback authorization, announced after Monday's close and funded by a fresh $20 million Takeda milestone payment.
On Nov. 16, Keros said its board approved a repurchase program of up to $5 million of common stock, hours after receiving a $20 million development milestone under its elritercept license with Takeda, triggered by first-patient dosing in the ELRiSE MF trial in myelofibrosis. Management also extended its cash runway guidance, stating that pro forma cash of roughly $259.5 million plus the milestone would fund operations into 2029 rather than the second half of 2028.
For a company valued at roughly $236 million, the signal matters more than the size. A clinical-stage biotech with no approved product choosing to return cash, rather than simply bank a partnership payment, is read as evidence of balance-sheet confidence. Still, $5 million represents only about 2% of market capitalization, and the program carries no obligation to buy a single share — a reminder that the fundamental news is supportive rather than transformative.
The scale of the reaction points to positioning as much as news. Tuesday's volume of more than 423,000 shares was roughly four times the three-month average of about 100,000, and turnover stayed active into Wednesday. With about 1.1 million shares sold short as of the Oct. 30 settlement — more than seven days of average trading volume — a decisive break higher likely forced some bears to cover into a thin book, a pattern consistent with an outsized move in a micro-cap biotech.
Technically, the advance reclaimed the stock's 60-session average near $11.05 on Tuesday and has now cleared the $11.50–$11.80 area that capped rallies in late October. The shares are up about 34% from the Nov. 10 closing low of $9.17.
The gain appears company-specific. No broad biotech or index-level catalyst coincided with the move, and no peer read-through was identified, which argues against sector sympathy as the cause. The elevated volume and the two-day, roughly 20% advance stand out against a stock that had shed more than half its value this year and tumbled 12.74% on Nov. 5 despite a headline third-quarter beat, when investors focused on the non-recurring nature of $40 million in milestone-driven license revenue. That post-earnings drawdown left the stock oversold and set up the current rebound, with an unscheduled $8.98 low on Nov. 10 marking the bottom.
On a 0–100 scale, where 0 means no meaningful news and a move that is routine for the stock, and 100 means transformative news accompanied by an extreme, rare price move, Keros earns 33 out of 100.
The verified catalyst is a $5 million buyback plus a $20 million milestone — real but modest relative to the company's size, and partly anticipated since the milestone was flagged in late September. The price reaction was meaningful but not extreme: at 6.45%, it was about 2.7 times the stock's typical daily move of roughly 2.4%, and moves of this magnitude occurred only three times in the past 60 sessions. Moderate news and a moderately unusual move combine into a mid-range score.
Attention now shifts back to the clinic. Management has said it would engage regulators in the second half of 2026 on the design of a Phase 2 study of rinvatercept in ALS, a milestone that could broaden the program's narrative. Initial Phase 2 Duchenne data are expected in the first half of 2027, while the elritercept Phase 3 program under Takeda — including RENEW and ELRiSE MF — should produce data in the 2028–2029 window. Fourth-quarter and full-year 2026 results are due in early March 2027.
Seven analysts cover the stock with a consensus Buy rating and an average 12-month target near $20, though ratings are split between four strong buys and three holds. The main risks are clinical: trial delays, enrollment slippage in Duchenne, widening losses as spending ramps, and revenue that will swing sharply with partner milestones rather than product sales.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies out of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics, and traded symbols, the page surfaces only those delivering the best results under current market conditions — a useful starting point for traders comparing systematic approaches with their own research. Explore the curated list to see which automated strategies are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
KROS saw its Momentum Indicator move above the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 79 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 27 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.596). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology